1. Home
  2. HRMY vs MIRM Comparison

HRMY vs MIRM Comparison

Compare HRMY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • MIRM
  • Stock Information
  • Founded
  • HRMY 2017
  • MIRM 2018
  • Country
  • HRMY United States
  • MIRM United States
  • Employees
  • HRMY 246
  • MIRM N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • HRMY Health Care
  • MIRM Health Care
  • Exchange
  • HRMY Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • HRMY 2.1B
  • MIRM 1.9B
  • IPO Year
  • HRMY 2020
  • MIRM 2019
  • Fundamental
  • Price
  • HRMY $36.08
  • MIRM $42.00
  • Analyst Decision
  • HRMY Buy
  • MIRM Strong Buy
  • Analyst Count
  • HRMY 9
  • MIRM 13
  • Target Price
  • HRMY $47.00
  • MIRM $56.23
  • AVG Volume (30 Days)
  • HRMY 1.2M
  • MIRM 278.8K
  • Earning Date
  • HRMY 10-29-2024
  • MIRM 11-15-2024
  • Dividend Yield
  • HRMY N/A
  • MIRM N/A
  • EPS Growth
  • HRMY N/A
  • MIRM N/A
  • EPS
  • HRMY 2.11
  • MIRM N/A
  • Revenue
  • HRMY $681,879,000.00
  • MIRM $264,375,999.00
  • Revenue This Year
  • HRMY $24.63
  • MIRM $73.07
  • Revenue Next Year
  • HRMY $18.04
  • MIRM $27.98
  • P/E Ratio
  • HRMY $17.14
  • MIRM N/A
  • Revenue Growth
  • HRMY 25.83
  • MIRM 128.34
  • 52 Week Low
  • HRMY $23.14
  • MIRM $23.14
  • 52 Week High
  • HRMY $41.61
  • MIRM $45.23
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 53.24
  • MIRM 63.67
  • Support Level
  • HRMY $32.37
  • MIRM $40.61
  • Resistance Level
  • HRMY $34.50
  • MIRM $42.75
  • Average True Range (ATR)
  • HRMY 1.87
  • MIRM 1.49
  • MACD
  • HRMY 0.12
  • MIRM 0.31
  • Stochastic Oscillator
  • HRMY 47.78
  • MIRM 83.70

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: